Cancer Vaccines
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you your search results in order of date.
5530 records returned
Aspirin kills 400% more people than H1N1 swine flu
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(NaturalNews) The CDC now reports that nearly 4,000 Americans have been killed by H1N1 swine flu. This number is supposed to sound big and scary, motivating millions of people to go out and pay good money to be injected with untested, unproven H1N1 vaccines. But let's put the number in perspective: Did you know that more than four times as many people are killed each year by common NSAID painkillers like aspirin?The July 1998 issue of The American Journal of Medicine explains it as follows:"Conservative calculations estimate that approximately 107,000 patients are hospitalized annually for nonsteroidal anti-inflammatory dr...
Source: NaturalNews.com - November 20, 2009 Category: Consumer Health Advice Source Type: news
Baby Boomers Don't Use Preventive ServicesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Only about a quarter of baby boomers take advantage of preventive services such as flu vaccines and cancer screenings, a new report from three health groups says. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - November 19, 2009 Category: Consumer Health News Source Type: news
Immune systems and ageingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion
This well-conducted scientific study looked at complex immune pathways in mice and appears to have been over-interpreted in the study’s press release and lay media reports, which suggest that these findings have important implications for seasonal flu and H1N1 vaccination.
It is important that scientists study the complex mechanisms in animal and human immunity, and this early research warrants further exploration. However, given the experimental nature of this animal study, it is premature to conclude that this study is relevant to flu vaccination programmes.
Links To The Headlines Elderly people succumb to ...
Source: NHS News Feed - November 19, 2009 Category: Consumer Health News Tags: Older people Source Type: news
Scancell Selects PharmaNet Development Group For SCIB1 Clinical TrialEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Scancell Holdings Plc, (PLUS:SCLP), the parent company of Scancell Limited ('Scancell'), the developer of innovative therapeutic cancer vaccines, is pleased to announce that it expects to commence its Phase I/II clinical trial with SCIB in the first half of 2010. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - November 19, 2009 Category: Pharmaceuticals Source Type: news
CDC Lifts HPV Vaccination Requirement For Young Female ImmigrantsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Starting Dec. 14, the U.S. will no longer require female immigrants seeking permanent resident status to be vaccinated against the human papillomavirus, the Centers for Disease Control and Prevention announced on Friday, the AP/San Francisco Chronicle reports. The new rule revises July 2008 guidelines that required female immigrants ages 11 through 26 seeking legal U.S. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 19, 2009 Category: Consumer Health News Tags: Cervical cancer / HPV vaccine Source Type: news
Fast generation of dendritic cells.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Dendritic cells (DC) are potent antigen presenting cells capable of inducing immune responses. DC are widely used as vaccine adjuvant in experimental clinical settings. DC-based vaccines are normally generated using a standard 8day DC protocol (SDDC). In attempts to shorten the vaccine production we have developed fast DC protocol by comparing two different fast DC protocols with SDDC. DC were evaluated by FACS analysis, and the optimal profile was considered: CD14(low), CD80(high), CD83(high), CD86(high), CCR7(high), HLA class I and II(high). FACS profiles were used as the selection criteria together with yield and mo...
Source: Cellular Immunology - November 18, 2009 Category: Allergy & Immunology Authors: Kvistborg P, Boegh M, Pedersen AW, Claesson MH, Zocca MB Tags: Cell Immunol Source Type: journals
Swine flu vaccine uptakeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Several newspapers have reported that pregnant women and other vulnerable people are refusing to have the swine flu vaccine. The Times reported that a poll of GPs found that only 46% of people who were offered the vaccine have accepted it, and one doctor estimated that only 5% of pregnant women have had it.
The news reports are based on a “snapshot” survey of 107 GPs. The survey asked how likely they were to hit the government’s target of vaccinating at least half of their patients who are under 65 and in high-risk groups this winter. GPs were also asked to estimate how many of the people who were offered the vacci...
Source: NHS News Feed - November 18, 2009 Category: Consumer Health News Tags: Swine flu Source Type: news
Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccinationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article focuses on how the frequency, phenotype, and functions of dendritic cells are altered during the
lymphopenic and recovery phases post-induction of lymphodepletion, and how they affect the anti-tumor responses of adoptively
transferred T cells.
Content Type Journal ArticleCategory ReviewDOI 10.1007/s00262-009-0792-6Authors
Mohamed Labib Salem, Medical University of South Carolina Surgery Department Charleston SC 29425 USADavid J. Cole, Medical University of South Carolina Surgery Department Charleston SC 29425 USA
Journal Cancer Immunology, ImmunotherapyOnline ISSN 1432-0851Print ISSN 0340-7004 (S...
Source: Cancer Immunology, Immunotherapy - November 18, 2009 Category: Cancer & Oncology Tags: cancer Immunology, Immunotherapy Source Type: journals
TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis modelEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Due to the pivotal role that dendritic cells (DC) play in eliciting functional anti-tumor T cell responses, immunotherapeutic
approaches utilizing DC-based vaccines have readily been exploited. It has been argued that, in the setting of immunotherapy,
mature DC will be more efficient at T cell priming and, therefore, required for effective vaccination. As TNF-alpha is commonly
used as a DC maturation factor, we have examined the efficacy of treatment with DC matured with TNF-alpha (DC-TNF) in a murine
model of melanoma. We have now shown that treatment with DC-TNF leads to an increase in the number ...
Source: Cancer Immunology, Immunotherapy - November 18, 2009 Category: Cancer & Oncology Tags: cancer Immunology, Immunotherapy Source Type: journals
A persistent virus vector confers superior anti-tumor immunity, compared with a non-persistent vectorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In this report, we show that a persistent gammaherpesvirus vector provides superior protection
against melanoma, relative to a non-persistent mutant of the same virus. These data suggest that vaccine vectors derived from
persistent viruses may perform better than those from acute viruses at mediating anti-tumor protection.
Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00262-009-0790-8Authors
Weijun Zhang, Dartmouth Medical School Department of Microbiology and Immunology 1 Medical Center Drive Lebanon NH 03756 USATong Zhang, Dartmouth Medical School Department of Microbiology and Immunology 1 Med...
Source: Cancer Immunology, Immunotherapy - November 18, 2009 Category: Cancer & Oncology Tags: cancer Immunology, Immunotherapy Source Type: journals
Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
HER-2/neu, overexpressed in breast cancer, is a source of immunogenic peptides that include GP2 and E75. Phase 2 testing of E75 as an adjuvant vaccine has suggested a clinical benefit. GP2, derived from the transmembrane portion of HER-2/neu, has differing binding characteristics and may be more immunogenic than E75. Results of the first phase 1 trial of GP2 peptide vaccine are presented.Disease-free, lymph node-negative, human leukocyte antigen (HLA)-A2+ breast cancer patients were enrolled. This dose escalation trial included 4 groups to determine safety and optimal GP2 peptide/granulocyte-macrophage colony-stimulating f...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Mark G. Carmichael, Linda C. Benavides, Jarrod P. Holmes, Jeremy D. Gates, Elizabeth A. Mittendorf, Sathibalan Ponniah, George E. Peoples Source Type: journals
Soluble B and T Lymphocyte Attenuator Possesses Antitumor Effects and Facilitates Heat Shock Protein 70 Vaccine-Triggered Antitumor Immunity against a Murine TC-1 Cervical Cancer Model In Vivo.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
B and T lymphocyte attenuator (BTLA)-herpesvirus entry mediator (HVEM) signaling coinhibitory pathway is believed to impair antitumor immune competences. An intriguing unresolved question is whether blockade of BTLA-HVEM guides an effective therapeutic tool against established tumors. To address this issue, we constructed a eukaryotic expression plasmid (psBTLA) that expressed the extracellular domain of murine BTLA (soluble form of BTLA), which could bind HVEM, the ligand of BTLA, and block BTLA-HVEM interactions. The data in this study showed that treatment by injection of psBTLA resulted in down-regulation of IL-10 ...
Source: Journal of Immunology - November 18, 2009 Category: Allergy & Immunology Authors: Han L, Wang W, Fang Y, Feng Z, Liao S, Li W, Li Y, Li C, Maitituoheti M, Dong H, Lai Z, Gao Q, Xi L, Wu M, Wang D, Zhou J, Meng L, Wang S, Ma D Tags: J Immunol Source Type: journals
Therapeutic Vaccination with an Interleukin-2–Interferon-γ-Secreting Allogeneic Tumor Vaccine in Patients with Progressive Castration-Resistant Prostate Cancer: A Phase I/II TrialEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Human Gene Therapy , Vol. 0, No. 0. (Source: Human Gene Therapy)
Source: Human Gene Therapy - November 17, 2009 Category: Genetics & Stem Cells Tags: article Source Type: journals
FDA approves cervical cancer vaccineEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Cervarix has won FDA approval for the prevention of cervical pre-cancers and cervical cancer associated with HPV-16 and HPV-18 for use in girls and young women (ages 10-25), according to GlaxoSmithKline. In clinical trials, the vaccine was shown to be 93% effective in the prevention of cervical pre-cancers associated with HPV -16 or 18, in women without evidence of current infection with, or prior exposure to, the same HPV type at the time of vaccination. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info
This week on Thrive: Nov. 9 – 13Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Here’s a quick look at what Thrive was up to last week.
An eco-perspective is explored on H1N1. Survivors of childhood brain cancer face a variety of late effects and why you need to get rid of your old glass thermometers. Children’s explores how babies understand expressions and emotions and offers tips on how to prepare your child for a flu vaccine. A new study reveals that parents are out of touch about knowing their kids’ stress levels and a Children’s expert gives tip on how to help kids cope with the stress of having a parent at war. The HealthMap team gives us our weekly H1N1 update and your questions are an...
Source: Thrive, Children's Hospital Boston - November 15, 2009 Category: Pediatrics Authors: Children's Hospital Boston staff Tags: All posts Ask the Mediatrician asthma brain cancer Center on Media and Child Health Children's Hospital Informatics Program flu Flu vaccine food stamps glass thermometers h1n1 HealthMap injury Injury Prevention Michael Rich p Source Type: organizations
Centers For Medicare & Medicaid Services Approves FDG PET For Cervical Cancer StagingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SNM applauds the Centers for Medicare & Medicaid Services' (CMS) decision to expand coverage of FDG PET for the initial staging of cervical cancer without previously imposed restrictions. "CMS' decision to expand coverage of FDG PET for the initial treatment strategy evaluation of cervical cancer is important for patient care," said Michael M. Graham, Ph.D., M.D., president of SNM. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 14, 2009 Category: Consumer Health News Tags: Cervical cancer / HPV vaccine Source Type: news
Centers For Medicare & Medicaid Services Approves FDG PET For Cervical Cancer StagingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SNM applauds the Centers for Medicare & Medicaid Services' (CMS) decision to expand coverage of FDG PET for the initial staging of cervical cancer without previously imposed restrictions. "CMS' decision to expand coverage of FDG PET for the initial treatment strategy evaluation of cervical cancer is important for patient care," said Michael M. Graham, Ph.D., M.D., president of SNM. (Source: MRI / PET / Ultrasound News From Medical News Today)
Source: MRI / PET / Ultrasound News From Medical News Today - November 14, 2009 Category: Radiology Tags: Cervical cancer / HPV vaccine Source Type: news
A to Z of what's wrong with AmericaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(NaturalNews) America has some major challenges. Lots of things could use some improvement. To help create this A-to-Z list of what's "wrong" with America, we tapped into the collective wisdom of our Facebook fans (http://facebook.naturalnews.com) who came up with a nice collection of both serious and funny answers to this question. (I added the descriptions.)By the way, just in case you're feeling more optimistic today (or want some inspiration), we also have an A to Z list of what's right with America! www.NaturalNews.comA to Z of what's wrong with America - The listA is for Aspartame - The magic powder that turns diet s...
Source: NaturalNews.com - November 14, 2009 Category: Consumer Health Advice Source Type: news
Cervical cancer vaccine hope for African womenEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
DAR ES SALAAM (Reuters) - So crammed is Tanzania's only cancer treatment center that Rukia Kondogoza, wrapped in bright kanga cloth, has to share her bed with another patient. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2009 Category: Consumer Health News Tags: healthNews Source Type: news
Disease Progression And Survival Of Cervical Cancer Patients: Genetic Changes Are Important IndicatorsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A study by Norwegian researchers published November 13 in the open-access journal PLoS Genetics reports that cervical cancer patients with specific changes in the cancer genome have a three- or fourfold increased risk of relapse after standard treatment compared to patients without these changes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 13, 2009 Category: Consumer Health News Tags: Cervical cancer / HPV vaccine Source Type: news
Disease Progression And Survival Of Cervical Cancer Patients: Genetic Changes Are Important IndicatorsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A study by Norwegian researchers published November 13 in the open-access journal PLoS Genetics reports that cervical cancer patients with specific changes in the cancer genome have a three- or fourfold increased risk of relapse after standard treatment compared to patients without these changes. Research suggests that specific genetic changes are critical steps in the progression of the disease towards an aggressive and treatment-resistant state. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 13, 2009 Category: Cancer & Oncology Tags: Cervical cancer / HPV vaccine Source Type: news
Facebook crowdsourced investigation exposes vaccine denials of SIGA TechnologiesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(NaturalNews) When you publish a hard-hitting story containing links to lots of little-known documents, you never know what kind of bizarre blow-back you'll receive. The latest episode of reactive strangeness occurred following our publication of the story about SIGA Technologies and the conflicts of interest found in Dr. Mehmet Oz's holding of 150,000 option shares in that company (http://www.naturalnews.com/027451_Dr_Mehmet_Oz_vaccines.html) even while pushing vaccines on TV. Shortly after publishing this article, NaturalNews was contacted by a public relations firm called KCSA Strategic Communications, which represents ...
Source: NaturalNews.com - November 13, 2009 Category: Consumer Health Advice Source Type: news
Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes. [Cancer Res 2009;69(22):8693–9] (Source: Cancer Research)
Source: Cancer Research - November 12, 2009 Category: Cancer & Oncology Authors: Vo, D. D., Prins, R. M., Begley, J. L., Donahue, T. R., Morris, L. F., Bruhn, K. W., de la Rocha, P., Yang, M.-Y., Mok, S., Garban, H. J., Craft, N., Economou, J. S., Marincola, F. M., Wang, E., Ribas, A. Tags: Immunology Source Type: journals
Poor value chlamydia screening programmeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
National Audit Office says £17m in savings could have been madeRelated items from OnMedicaCervical cancer vaccine choice criticisedMiddle-aged women may benefit from HPV vaccine Third of schools offer sex education clinicsGP incentives not always best for improving healthy lifestyleOver 45s take risks with their sexual health (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 12, 2009 Category: UK Health Source Type: news
Heat shock protein 110 improves the anti-tumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Several strategies have been used to enhance the vaccine-induced immunity of peptide vaccines and effective therapeutic benefits, including the utilization of heat shock proteins (HSP), especially the HSP70 family. HSP110 exhibits a higher binding affinity with protein and is capable of enhancing the immunogenicity of protein antigens; however, whether HSP110 can also increase the efficiency of peptide vaccine remains unclear. Here, we investigated mHSP110 as a chaperone immunoadjuvant to enhance the immune response to HPV16 oncoprotein E7-derived CTL epitope E7(49-57) in a mouse model. We developed the HSP110-E7(49-57...
Source: Cancer Biology and Therapy - November 11, 2009 Category: Cancer & Oncology Authors: Ren F, Xu Y, Mao L, Ou R, Ding Z, Zhang X, Tang J, Li B, Jia Z, Tian Z, Ni B, Wu Y Tags: cancer Biol Ther Source Type: journals
HPV Vaccine Clears Viral Infection And May Reduce Cancerous LesionsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 11, 2009 Category: Cancer & Oncology Tags: Cervical cancer / HPV vaccine Source Type: news
HPV Vaccine Clears Viral Infection And May Reduce Cancerous LesionsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 11, 2009 Category: Consumer Health News Tags: Cervical cancer / HPV vaccine Source Type: news
Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
We describe herein a novel HLA-A*0201-restricted epitope, encompassing amino acids 828–836 (residues QIAKGMSYL),
which is naturally presented by various HER-2/neu
+ tumor cell lines. HER-2/neu(828-836), [HER-2(9828)], possesses two anchor residues and stabilized HLA-A*0201 on T2 cells in a concentration-dependent Class I binding assay.
This peptide was stable for 3.5 h in an off-kinetic assay. HER-2(9828) was found to be immunogenic in HLA-A*0201 transgenic (HHD) mice inducing peptide-specific and functionally potent CTL and
long-lasting anti-tumor immunity. Most important, using HLA-A*0201 pentamer analysis we ...
Source: Cancer Immunology, Immunotherapy - November 11, 2009 Category: Cancer & Oncology Tags: cancer Immunology, Immunotherapy Source Type: journals
Early tests on cervical cancer drugsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion
This small study has shown that the oestrogen receptor blockers fulvestrant and raloxifene can treat cervical cancers in genetically engineered mice with this disease. Although these results suggest that the drugs may be worth investigating further for potential use in human cervical cancer, they may not represent the effects that the drugs would have in humans. As the researchers note, “Although our transgenic mouse model for HPV-associated cervical cancer recapitulates most aspects of human cervical cancer, it is obvious that further study is needed to determine whether this proposed model is relevant to h...
Source: NHS News Feed - November 10, 2009 Category: Consumer Health News Tags: cancer Medical practice Source Type: news
Age-Specific Evaluation Of HPV DNA Testing Vs. Cytology ScreeningEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Human papillomavirus (HPV) DNA testing with cytology triage is more sensitive than conventional cytology screening for detecting cervical lesions, according to a new study published online November 9 in the Journal of the National Cancer Institute. Cytology triage in HPV-positive women can improve specificity. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 10, 2009 Category: Consumer Health News Tags: Cervical cancer / HPV vaccine Source Type: news
Age-Specific Evaluation Of HPV DNA Testing Vs. Cytology ScreeningEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Human papillomavirus (HPV) DNA testing with cytology triage is more sensitive than conventional cytology screening for detecting cervical lesions, according to a new study published online November 9 in the Journal of the National Cancer Institute. Cytology triage in HPV-positive women can improve specificity. (Source: Genetics News From Medical News Today)
Source: Genetics News From Medical News Today - November 10, 2009 Category: Genetics & Stem Cells Tags: Cervical cancer / HPV vaccine Source Type: news
FDA Approves Cervical Cancer VaccineEmail this article to a colleague.
Save this article to My Clippings.
1 CommentDiscuss or comment on this article.
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s human papillomavirus bivalent (types 16 and 18) vaccine, recombinant (Cervarix) for the prevention of cervical precancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10–25).
Women are at risk of HPV infecti (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info
FDA-Approved Drugs Eliminate, Prevent Cervical Cancer In MiceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have eliminated cervical cancer in mice with two FDA-approved drugs currently used to treat breast cancer and osteoporosis. Published in this week's (Nov. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 10, 2009 Category: Consumer Health News Tags: Cervical cancer / HPV vaccine Source Type: news
Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A major challenge for developing effective therapeutic vaccines against cancer is overcoming immunologic tolerance to tumor-associated antigens that are expressed on both malignant cells and normal tissues. Herein, we describe a novel vaccination approach, TriVax, that uses synthetic peptides representing CD8 T-cell epitopes, Toll-like receptor agonists that function as potent immunologic adjuvants and costimulatory anti-CD40 antibodies to generate large numbers of high-avidity antigen-reactive T cells capable of recognizing and killing tumor cells. Our results show that TriVax induced huge numbers of long-lasting anti...
Source: Cell Research - November 10, 2009 Category: Cytology Authors: Cho HI, Celis E Tags: cancer Res Source Type: journals
Partial CD4 Depletion Reduces Regulatory T Cells Induced by Multiple Vaccinations and Restores Therapeutic Efficacy.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSION: These results suggest that CD4+ T(reg) cells limit the efficacy of multiple vaccinations and that timed partial depletion of CD4+ T cells may reduce suppression and "tip-the-balance" in favor of therapeutic antitumor immunity. The recent failure of large phase III cancer vaccine clinical trials, wherein patients received multiple vaccines, underscores the potential clinical relevance of these findings. (Clin Cancer Res 2009;15(22):6881-90).
PMID: 19903784 [PubMed - as supplied by publisher] (Source: Cell Research)
Source: Cell Research - November 10, 2009 Category: Cytology Authors: Lacelle MG, Jensen SM, Fox BA Tags: Clin cancer Res Source Type: journals
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSIONS: High immune response rates for this multipeptide vaccine were achieved, but CD8(+) and CD4(+) T-cell responses were lower when administered with GM-CSF. These data challenge the value of local GM-CSF as a vaccine adjuvant in humans. (Clin Cancer Res 2009;15(22):7036-44).
PMID: 19903780 [PubMed - as supplied by publisher] (Source: Cell Research)
Source: Cell Research - November 10, 2009 Category: Cytology Authors: Slingluff CL, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA Tags: Clin cancer Res Source Type: journals
Immunostimulation Versus Immunosuppression after Multiple Vaccinations: the Woes of Therapeutic Vaccine Development.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Three articles in this issue of Clinical Cancer Research show how multiple vaccinations can lead to immunosuppression. Moreover, two studies in patients show that granulocyte macrophage colony-stimulating factor (GM-CSF) as an adjuvant immunostimulant to different kind of vaccines can lead to adverse outcome in terms of relapse-free and overall survival. Modulation of regulatory T-cell activity may be required to overcome this outcome and may be crucial for the successful development of therapeutic vaccines. (Clin Cancer Res 2009;15(22):6745-7).
PMID: 19903779 [PubMed - as supplied by publisher] (Source: Cell Research)
Source: Cell Research - November 10, 2009 Category: Cytology Authors: Eggermont AM Tags: Clin cancer Res Source Type: journals
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSION: These data suggest that GM-CSF is not helpful as an immune adjuvant in this dose and schedule and raise concern that it may be harmful. Based on the discordant findings of an immune endpoint and clinical outcome, the use of such surrogate endpoints in selecting treatments for further evaluation must be done with a great deal of caution. (Clin Cancer Res 2009;15(22):7029-35).
PMID: 19903777 [PubMed - as supplied by publisher] (Source: Cell Research)
Source: Cell Research - November 10, 2009 Category: Cytology Authors: Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL Tags: Clin cancer Res Source Type: journals
T-Cell Responses to Cyclin B1 Are Not Restricted to p53-Overexpressing Tumors.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
To the Editors: In their elegant study, Sorensen et al. showed the existence of a T-cell response to two cyclin B1-derived peptides in patients with advanced-stage breast cancer, confirming initial observations by Kao that cyclin B1 is an interesting target for immunotherapy (1, 2). However, the authors reported the absence of cyclin B1-specific T cells in 10 of 10 healthy donors and concluded that they are only present after tumor-driven immune activation in patients with p53/cyclin B1-overexpressing tumors. This is in contrast to our findings (3).(1) We have characterized the cyclin B1 peptides 44(ALGDIGNKV), 204(ILI...
Source: Clinical Cancer Research - November 10, 2009 Category: Cancer & Oncology Authors: von Bergwelt-Baildon MS, Shimabukuro-Vornhagen A, Klein-Gonzalez N, Kondo E Tags: Clin cancer Res Source Type: journals
The fusion protein of HSP65 with tandem repeats beta-hCG acting as a potent tumor vaccine in suppressing Hepatocarcinoma.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
It has been demonstrated that the beta-subunit of Human chorionic gonadotropin (beta-hCG) is ectopically expressed on a variety of human cancers of different histological types and has been used as an antigenic target in anti-cancer vaccines. We engineered a fusion protein by fusing 10 tandemly repeated copies of the 10-residue sequence of beta-hCG (109-118)in CTP37combined with beta-hCG C-terminal 37 peptides to mycobacterial heat-shock protein 65 and immunized mice via subcutaneous injection. Humoral immune and cellular immune responses were effectively elicited. High titer of anti-beta-hCG antibody was detected in i...
Source: International Immunopharmacology - November 10, 2009 Category: Allergy & Immunology Authors: Hu X, Zhang Y, Lin M, Lu Y, Zhang Y, Zhang H, Chen Y, Hou J, Xing Y, Jin L, Cao R, Liu J Tags: Int Immunopharmacol Source Type: journals
This week on Thrive: Nov. 2 – 6Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Here’s a quick look at what Thrive was up to last week.
Read why the days of jumping back into a game after a possible concussion are over. A new study shows that adult survivors of childhood cancer are much more likely to experience suicidal thoughts than their peers. Children’s expert Ellen Hanson, PhD, questions whether autism really is on the rise. An experimental heart valve saves a child with H1N1. Children’s has established and unprecedented partnership with the state’s largest health plans. The HealthMap team gives its weekly H1N1 update. Children’s Dennis Rosen, MD, questions whether sleeping late can ke...
Source: Thrive, Children's Hospital Boston - November 8, 2009 Category: Pediatrics Authors: Children's Hospital Boston staff Tags: All posts Ask the Mediatrician autism cancer Center on Media and Child Health CEO blog Children's Hospital Informatics Program concussion flu Flu vaccine h1n1 Health Reform HealthMap injury Injury Prevention James Mandell blo Source Type: organizations
Safety of Gardasil VaccineEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
It's been about 18 months since the vaccine Gardasil has been on the market. The drug is designed to protect millions of girls and women against cervical cancer by preventing the human papilloma virus (HPV).
Today Barbara Lewis is joined by Dr. Marcia Shew, a specialist in adolescent medicine at Indiana University. She's been tracking the vaccine since its introduction. Shew discusses the usefu.... (Source: Sound Medicine)
Source: Sound Medicine - November 8, 2009 Category: Global & Universal Authors: Sound Medicine Source Type: info
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cellsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In this study, we determined that GM-CSF was one of the tumor-derived soluble factors that induced differentiation of CD11b-Gr1-
progenitor cells from within monocytic/granulocytic bone marrow cells into CD11b+Gr1+ cells. We also showed that CD11b+Gr1+
cells in FVBN202 mice consisted of CD11b+Ly6G-Ly6C+ suppressive and CD11b+Ly6G+Ly6C+ non-suppressive subsets. Previously reported
variations between tumor-free and tumor-bearing animals in the function of their CD11b+Gr1+ cells were found to be due to
the variations in the proportion of these two subsets. Therefore, increasing ratios of CD11b+Gr1+ cells derived from tumo...
Source: Breast Cancer Research and Treatment - November 7, 2009 Category: Cancer & Oncology Tags: Breast cancer Research and Treatment Source Type: journals
Associated Press declares war on alternative medicine (opinion)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(NaturalNews) The Associated Press has declared war on alternative medicine, publishing a series of stories attacking everything from nutritional therapies to bioidentical hormones. These stories, which are syndicated across thousands of websites around the world, are prefaced with the following highly-opinionated "Editor's Note":EDITOR'S NOTE: Ten years and $2.5 billion in research have found no cures from alternative medicine. Yet these mostly unproven treatments are now mainstream and used by more than a third of all Americans. This is one in an occasional series examining their use and potential risks.What this note re...
Source: NaturalNews.com - November 7, 2009 Category: Consumer Health Advice Source Type: news
Guided Therapeutics Non-Invasive Cervical Cancer Detection Device Trial Confirms Current Tests Miss Disease; Create High False Positive RatesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Results of the FDA pivotal clinical trial for the LightTouch™ Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 7, 2009 Category: Consumer Health News Tags: Cervical cancer / HPV vaccine Source Type: news
Guided Therapeutics Non-Invasive Cervical Cancer Detection Device Trial Confirms Current Tests Miss Disease; Create High False Positive RatesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Results of the FDA pivotal clinical trial for the LightTouch™ Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI). (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 7, 2009 Category: Cancer & Oncology Tags: Cervical cancer / HPV vaccine Source Type: news
Experimental Vaccine Shows Promise In Treating Precancerous Vulvar Growths, Study SaysEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
An experimental vaccine to treat precancerous vulvar growths eliminated the growths in nine of 20 women participating in a small trial, according to a study published in the New England Journal of Medicine, Reuters reports. The vaccine is intended to treat vulvar growths -- known as vulvar intraepithelial neoplasia -- that are caused by the human papillomavirus and can lead to vulvar cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 6, 2009 Category: Consumer Health News Tags: Women's Health / Gynecology Source Type: news
New Synthetic Molecules Trigger Immune Response To HIV And Prostate CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. (Source: Immune System / Vaccines News From Medical News Today)
Source: Immune System / Vaccines News From Medical News Today - November 6, 2009 Category: Allergy & Immunology Tags: HIV / AIDS Source Type: news
Biosensor To Help Enlist Cancer Resistance Fighters?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters. (Source: Immune System / Vaccines News From Medical News Today)
Source: Immune System / Vaccines News From Medical News Today - November 6, 2009 Category: Allergy & Immunology Tags: cancer / Oncology Source Type: news
Helix BioPharma Corp. Completes Enrollment In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital WartsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial. The double-blind and placebo-controlled Phase II trial is underway at multiple centers in Germany and Sweden. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 6, 2009 Category: Consumer Health News Tags: Cervical cancer / HPV vaccine Source Type: news
